6th European Pharmacovigilance Congress

ABSTRACT

The proceedings contain 25 papers. The topics discussed include methodologies for evaluating drugs' benefit' risk balance as per current guidelines;CIOMS Working Group XII on benefit'risk of medicines;what are severe cutaneous adverse reactions (SCARs)? A dermatologic perspective;is artificial intelligence in pharmacovigilance on a 'hype cycle'?;artificial intelligence in pharmacovigilance;characterizing the safety profile of hematopoietic stem cell (HSC) gene therapies;long-term safety issues associated with genetic therapies;efficient road to reliable pharmacovigilance regulatory intelligence;post-marketing data collection and evidence evaluation;Uppsala monitoring center and WHO program of international drug monitoring;and safety monitoring of COVID-19 therapy and vaccines.